Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminase

International Journal of Cancer

Volumn 123, Issue 8, 2008, Pages 1950-1955

  Bowles, Tawnya L ^a   Kim, Randie ^a   Galante, Joseph ^a   Parsons, Colin M ^a   Virudachalam, Subbulakshmi ^a   Kung, Hsing Jien ^a   Bold, Richard J ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Arginine; Arginine deiminase; Pancreatic cancer

Indexed keywords

ARGININE DEIMINASE; ARGININOSUCCINATE SYNTHASE; CASPASE; EXBB PROTEIN; MACROGOL 400;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CELL DEATH; CELL GROWTH; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; XENOGRAFT;

ANIMALS; APOPTOSIS; ARGININE; ARGININOSUCCINATE SYNTHASE; CELL GROWTH PROCESSES; HUMANS; HYDROLASES; IMMUNOHISTOCHEMISTRY; MICE; MICE, NUDE; PANCREATIC NEOPLASMS; POLYETHYLENE GLYCOLS; RNA, MESSENGER; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 51949087021     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23723     Document Type: Article

References (43)

1. Ascierto PA, Scala S, Castello G, Daponte A, Simeone E, Ottaiano A, Beneduce G, De Rosa V, Izzo F, Melucci MT, Ensor CM, Prestayko AW, et al. Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies. J Clin Oncol 2005;23:7660-8.
2. Izzo F, Marra P, Beneduce G, Castello G, Vallone P, De Rosa V, Cremona F, Ensor CM, Holtsberg FW, Bomalaski JS, Clark MA, Ng C, et al. Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies. J Clin Oncol 2004;22:1815-22.
3. Viera Pinheiro JP, Boos J. The best way to use asparaginase in childhood acute lymphocytic leukemia: still to be defined? Br J Haematol 2004;125:117-27.
4. Gilroy E. The influence of arginine upon the growth rate of a transplantable tumour in the mouse. Biochem J 1930;24:589-95.
5. Gonzalez GG, Byus CV. Effect of dietary arginine restriction upon ornithine and polyamine metabolism during two-stage epidermal carcinogenesis in the mouse. Cancer Res 1991;51:2932-9.
6. Yeatman TJ, Risley GL, Brunson ME. Depletion of dietary arginine inhibits growth of metastatic tumor. Arch Surg 1991;126:1376-32.
7. Morris SM. Arginine metabolism: enzymology, nutrition, and clinical significance. J Nutr 2004;134:2743S-7S.
8. Curis E, Nicolis I, Moinard C, Osowska S, Zerrouk N, Bénazeth S, Cynober L. Almost all about citrulline in mammals. Amino Acids 2005;29:177-205.
9. O'Brien WE. Isolation and characterization of argininosuccinate synthetase from human liver. Biochemistry 1979;18:5353-6.
10. Husson A, Brasse-Lagnel C, Fairand A, Renouf S, Lavoinne A. Argininosuccinate synthetase from the urea cycle to the citrulline-NO cycle. Eur J Biochem 2003;270:1887-99.
11. Noh EJ, Kang SW, Shin YJ, Kim DC, Park IS, Kim MY, Chun BG, Min BH. Characterization of mycoplasma arginine deiminase expressed in E. coli and its inhibitory regulation of nitric oxide synthesis. Mol Cells 2002;13:137-43.
12. Holtsberg FW, Ensor CM, Steiner MR, Bomalaski JS, Clark MA. Poly(ethylene glycol) (PEG) conjugated arginine deiminase: effects of PEG formulations on its pharmacological properties. J Control Release 2002;80:259-71.
13. Ensor CM, Holtsberg FW, Bomalaski JS, Clark MA. Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo. Cancer Res 2002;62:5443-50.
14. Gong H, Zölzer F, von Recklinghausen G, Rössler J, Breit S, Havers W, Fotsis T, Schweigerer L. Arginine deiminase inhibits cell proliferation by arresting cell cycle and inducing apoptosis. Biochem Biophys Res Commun 1999;261:10-14.
15. Wheatley DN, Campbell E. Arginine deprivation, growth inhibition and tumour cell death: deficient utilization of citrulline by malignant cells. Br J Cancer 2003;89:573-6.
16. Shen LJ, Lin WC, Belloussow K, Shen WC. Resistance to the antiproliferative activity of recombinant arginine deiminase in cell culture correlates with the endogenous enzyme, argininosuccinate synthetase. Cancer Lett 2003;191:165-70.
17. Shen LJ, Belloussow K, Shen WC. Modulation of arginine metabolic pathways as the potential anti-tumor mechanism of recombinant arginine deiminase. Cancer Lett 2006;231:30-5.
18. Yoon CY, Shim YJ, Kim EH, Lee JH, Won NH, Kim JH, Park IS, Yoon DK, Min BH. Renal cell carcinoma does not express argininosuccinate synthetase and is highly sensitive to arginine deprivation via arginine deiminase. Int J Cancer 2007;120:897-905.
19. Curley SA, Bomalaski JS, Ensor CM, Holtsberg FW, Clark MA. Regression of hepatocellular cancer in a patient treated with arginine deiminase. Hepatogastroenterology 2003;50:1214-16.
20. Dillon BJ, Holtsberg FW, Ensor CM, Bomalaski JS, Clark MA. Biochemical characterization of the arginine degrading enzymes arginase and arginine deiminase and their effect on nitric oxide production. Med Sci Monit 2002;8:BR248-53.
21. Fahy BN, Schlieman MG, Mortenson MM, Virudachalam S, Bold RJ. Targeting BCL-2 overexpression in various human malignancies through NF-κB inhibition by the proteasome inhibitor bortezomib. Cancer Chemother Pharmacol 2005;56:46-54.
22. Cooper C, Packer N, Williams K. Amino acid analysis protocols, methods in molecular biology, vol. 159. Totawa, NJ: Humana Press, 2000.
23. Ozols J. Amino acid analysis. In: Deutscher MP, ed. Guide to protein purification, methods in enzymology, vol. 182. San Diego, CA: Academic Press, 1990;587-601.
24. Jackson MJ, Allen SJ, Beaudet AL, O'Brien WE. Metabolite regulation of argininosuccinate synthetase in cultured human cells. J Biol Chem 1988;263:16388-94.
25. Schimke RT. Enzymes of arginine metabolism in mammalian cell culture. J Biol Chem 1964;239:136-145.
26. Wheatley DN. Arginine deprivation and metabolomics: important aspects of intermediary metabolism in relation to the differential sensitivity of normal and tumour cells. Sem Cancer Biol 2005;15:247-53.
27. Rouge C, Des Robert C, Robins A, Le Bacquer O, Volteau C, De La Cochetière MF, Darmaun D. Manipulation of citrulline availability in humans. Am J Physiol Gastrointest Liver Physiol 2007;293:G1061-7.
28. Cheng PN, Lam TL, Lam WM, Tsui SM, Cheng AS, Lo WH, Leung YC. Pegylated recombinant human arginase (rhArg-peg5000mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion. Cancer Res 2007;67:309-17.
29. Rose WC, Haines WJ, Warner DT. The amino acid requirements of man: the role of lysine, arginine, and tryptophan. J Biol Chem 1954;106:421-30.
30. Brasse-Lagnel C, Fairand A, Lavoinne A, Husson A. Glutamine stimulates argininosuccinate synthetase gene expression through cytosolic O-glycosylation of Sp1 in Caco-2 cells. J Biol Chem 2002;278:52504-10.
31. Quillard M, Husson A, Lavoinne A. Glutamine increase argininosuccinate synthetase mRNA levels in rat hepatocytes. The involvement of cell swelling. Eur J Biochem 1996;236:56-59.
32. Anderson GM, Freytag SO. Synergistic activation of a human promoter in vivo by transcription factor Sp1. Mol Cell Biol 1991;11:1935-43.
33. Hattori Y, Campbell EB, Gross SS. Argininosuccinate synthetase mRNA and activity are induced by immunostimulants in vascular smooth muscle. Role in the regeneration of arginine for nitric oxide synthesis. J Biol Chem 1994;269:9405-8.
34. Brasse-Lagnel C, Lavoinne A, Fairand A, Vavasseur K, Husson A. IL-1beta stimulates argininosuccinate synthetase gene expression through NF-kappaB in Caco-2 cells. Biochim 2005;87:403-9.
35. Nagasaki A, Gotoh T, Takeya M, Yu Y, Takiguchi M, Matsuzaki H, Takatsuki K, Mori M. Coinduction of nitric oxide synthase, argininosuccinate synthetase, and arginiosuccinate lyase in lipopolysaccharide-treated rats. RNA blot, immunoblot, and immunohistochemical analysis. J Biol Chem 1996;271:2658-62.
36. Szlosarek PW, Klabatsa A, Pallaska A, Sheaff M, Smith P, Crook T, Grimshaw MJ, Steele JP, Rudd RM, Balkwill FR, Fennell DA. In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion. Clin Cancer Res 2006;12:7126-31.
37. Tsujimoto Y, Shimizu S. Another way to die: autophagic programmed cell death. Cell Death Differ 2005;12 (Suppl 2):1528-34.
38. Gozuacik D, Kimchi A. Autophagy as a cell death and tumor suppressor mechanism. Oncogene 2004;23:2891-906.
39. Klionsky DJ, Emr SD. Autophagy as a regulated pathway of cellular degradation. Science 2000;290:1717-21.
40. Klionsky DJ. Autophagy: from phenomenology to molecular understanding in less than a decade. Nature Rev Mol Cel Biol 2007;8:931-7.
41. Amaravadi RK, Thompson CB. The roles of therapy-induced autophagy and necrosis in cancer treatment. Clin Cancer Res 2007;13:7271-9.
42. Cut Q, Tashiro S, Onodera S, Minami M, Ikejima T. Autophagy preceded apoptosis in oridonin-treated human breast cancer MCF-7 cells. Biol Pharm Bull 2007;30:859-64.
43. Abedin MJ, Wang D, McDonnell MA, Lehmann U, Kelekar A. Autophagy delays apoptotic death in breast cancer cells following DNA damage. Cell Death Differ 2007;14:500-10.